Proactive Investors
12 Jun 2026, 08:15 UTC · 2h ago
Allergy Therapeutics to showcase pollen and food allergy progress
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
12 Jun 2026, 08:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Allergy Therapeutics' Phase I/IIa PROTECT trial for its VLP Peanut candidate met its primary endpoint, demonstrating a benign safety profile and a dose-response in tolerogenic immune responses. — Meeting a primary endpoint and achieving clinical proof-of-concept is a major de-risking event for a biotech pipeline asset.
+0.60ACG Metals beat its 2025 production guidance due to sharply falling costs at the Gediktepe mine in Turkey. — Outperforming production guidance and reducing operational costs directly improves margins and cash flow.
+0.40ACG Metals is on track to become a copper producer this year, with expansion works proceeding on time and on budget. — Transitioning from an explorer/developer to a producer is a critical value-inflection point for mining companies.
+0.30Continue reading
6 related stories
Search tags
Allergy Therapeutics reported blinded first-year safety data from its Phase III trial of Grass MATA MPL, showing a benign safety profile and low discontinuation rates. — Positive safety data in a late-stage Phase III trial reduces the risk of regulatory rejection, though it is less impactful than efficacy data.
+0.20Which stocks this story touches
The company beat 2025 production guidance, saw costs fall sharply, and is on track to become a copper producer.
The company reported positive clinical proof-of-concept data and met primary endpoints for its VLP Peanut candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
4h ago
